Automation in the biopharma sector in the next ten years will be driven by automated solutions such as artificial intelligence and robotics, as per a study.
As per a market report, advancements in real-time supply chain operations are projected to fuel the cell and gene therapy supply chain and logistics industry.
According to the U.S. Senate committee, geographic concentration and a lack of visibility into sourcing pose challenges to the supply of some critical drugs.
As per recent report, the cold chain products will continue to see a surge across Europe that is twice as much as the non-cold chain products throughout 2024.
